Affimed N.V. (AFMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
AFMD POWR Grades
- AFMD scores best on the Value dimension, with a Value rank ahead of 80.66% of US stocks.
- The strongest trend for AFMD is in Momentum, which has been heading down over the past 47 weeks.
- AFMD ranks lowest in Momentum; there it ranks in the 4th percentile.
AFMD Stock Summary
- For AFMD, its debt to operating expenses ratio is greater than that reported by merely 6.54% of US equities we're observing.
- With a year-over-year growth in debt of -68.54%, Affimed NV's debt growth rate surpasses only 5.17% of about US stocks.
- Revenue growth over the past 12 months for Affimed NV comes in at 400.05%, a number that bests 97.91% of the US stocks we're tracking.
- Stocks that are quantitatively similar to AFMD, based on their financial statements, market capitalization, and price volatility, are AUTL, ALPN, VCNX, FULC, and SYRS.
- AFMD's SEC filings can be seen here. And to visit Affimed NV's official web site, go to www.affimed.com.
AFMD Price Target
For more insight on analysts targets of AFMD, see our AFMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.75 | Average Broker Recommendation | 1.25 (Strong Buy) |
AFMD Stock Price Chart Interactive Chart >
AFMD Price/Volume Stats
| Current price | $6.30 | 52-week high | $11.74 |
| Prev. close | $6.39 | 52-week low | $3.09 |
| Day low | $6.20 | Volume | 885,880 |
| Day high | $6.40 | Avg. volume | 2,140,854 |
| 50-day MA | $6.56 | Dividend yield | N/A |
| 200-day MA | $7.35 | Market Cap | 619.21M |
Affimed N.V. (AFMD) Company Bio
Affimed NV is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The company was founded in 2000 and is based in Heidelberg, Germany.
Latest AFMD News From Around the Web
Below are the latest news stories about Affimed NV that investors may wish to consider to help them evaluate AFMD as an investment opportunity.
New Strong Sell Stocks for September 13thAFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021. |
Affimed NV (NasdaqGM:AFMD) (AFMD) Q2 2021 Earnings Call TranscriptOn the call today, we have the following members of our management team, Dr. Adi Hoess, our Chief Executive Officer; Andreas Harstrick, our Chief Medical Officer; Arndt Schottelius, our Chief Scientific Officer; Wolfgang Fischer, our Chief Operating Officer; and Angus Smith, our Chief Financial Officer. Today's discussion contains projections and forward-looking statements regarding future events. |
Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue EstimatesAffimed N.V. (AFMD) delivered earnings and revenue surprises of -171.43% and -13.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? |
Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational ProgressAFM13 monotherapy: Enrollment is on track and expected to be completed in the first half of 2022.AFM13 combination with NK cells: All three dose escalation cohorts are fully enrolled with no dose limiting toxicities observed; additional patients are being enrolled at the highest dose level to confirm safety and generate additional efficacy data; data update expected at a scientific conference in Q4 2021.AFM24 monotherapy: Based on current data, doses used in cohorts 5 (320 mg) and 6 (480 mg) are |
Affimed N.V. hosts conference call for investorsThe company, Affimed N.V., is set to host investors and clients on a conference call on 9/8/2021 8:02:21 PM. The call comes after the company''s earnings, which are set to be announced on 9/8/2021.Investors, or members of the public who wish to dial in, can join the call by visiting |
AFMD Price Returns
| 1-mo | 9.95% |
| 3-mo | -23.54% |
| 6-mo | -19.02% |
| 1-year | 65.79% |
| 3-year | 44.00% |
| 5-year | 107.24% |
| YTD | 8.25% |
| 2020 | 112.41% |
| 2019 | -11.90% |
| 2018 | 139.23% |
| 2017 | -27.78% |
| 2016 | -74.72% |
Continue Researching AFMD
Want to see what other sources are saying about Affimed NV's financials and stock price? Try the links below:Affimed NV (AFMD) Stock Price | Nasdaq
Affimed NV (AFMD) Stock Quote, History and News - Yahoo Finance
Affimed NV (AFMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...